Table 4.
Diagnostic performance of VAB and imaging in the TNBC and HER2-positive subgroups
| Diagnostic metrics | TNBC [n = 126] |
HER2+, HR− [n = 36] |
HER2+, HR+ [n = 75] |
|---|---|---|---|
| VAB | |||
| Accuracy | 87.3% (110/126) | 86.1% (31/36) | 90.7% (68/75) |
| Sensitivity | 71.4% (40/56) | 50.0% (5/10) | 80.0% (28/35) |
| Specificity | 100.0% (70/70) | 100.0% (26/26) | 100% (40/40) |
| PPV | 100.0% (40/40) | 100.0% (5/5) | 100% (28/28) |
| NPV | 81.4% (70/87) | 83.9% (26/31) | 85.1% (40/47) |
| Imaging | |||
| Accuracy | 67.5% (85/126) | 58.3% (21/36) | 61.3% (46/75) |
| Sensitivity | 76.8% (43/56) | 80.0% (8/10) | 68.6% (24/35) |
| Specificity | 60.0% (42/72) | 50.0% (13/26) | 55.0% (22/40) |
| PPV | 60.6 (43/71) | 38.1% (8/21) | 57.1% (24/42) |
| NPV | 76.4 (42/55) | 86.7% (13/15) | 66.7% (22/33) |
PPV positive predictive value, NPV negative predictive value, VAB vacuum-assisted biopsy, TNBC triple-negative breast cancer, HER2 human epidermal growth factor receptor, HR hormone receptor